

Product Information

SIGMAFAST™ OPD

Tablet set

P9187**Product Description**

The SIGMAFAST™ OPD (*o*-phenylenediamine dihydrochloride) tablet set is designed for use as a soluble substrate to detect horseradish peroxidase (HRP) activity in Enzyme Immunoassays (EIA and ELISA).¹⁻³ EIA/ELISA applications utilizing OPD may be read in timed assays or stopped with dilute acid solutions for delayed readings. The SIGMAFAST™ OPD tablet set requires only the addition of water, with no additional buffers or steps, to prepare an active substrate solution.

Several dissertations⁴⁻⁹ have cited use of product P9187 in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Components

Each SIGMAFAST™ OPD tablet set consists of one OPD tablet (silver foil) and one urea hydrogen peroxide tablet (gold foil). The tablets are individually packaged in foil packets.

Storage/Stability

Store the tablet sets at 2-8 °C. The tablets are very hygroscopic and light-sensitive, and should be stored in the protective foil packets.

The Substrate Solution is light-sensitive and should be protected from direct sunlight or UV sources in a tightly capped amber bottle.

Preparation Instructions

Each tablet set, when dissolved in 20 mL of water, provides 20 mL of ready-to-use substrate with final concentrations of:

- 0.4 mg/mL OPD
 - 0.4 mg/mL urea hydrogen peroxide
 - 0.05 M phosphate-citrate, pH 5.0
1. Remove the required number of OPD and urea hydrogen peroxide tablets for the assay.
 2. Return the box to the refrigerator.
 3. Allow the tablets to reach room temperature.
 4. Open one OPD tablet package (silver foil) and one urea hydrogen peroxide tablet package (gold foil).
 5. Drop the tablets into an amber bottle containing 20 mL of water. **Avoid skin contact with the tablets.**
 6. Vortex until dissolved.

The Substrate Solution is now ready for use. For best results, the Substrate Solution should be used within one hour.

Procedure

1. After the EIA/ELISA reaction with the HRP-conjugated antibody is completed, wash the plate thoroughly to remove unbound conjugate.
2. Add 200 µL of the Substrate Solution to each well. Incubate the plate, in the dark, for 30 minutes at room temperature.
3. After the incubation period, read the plate at 450 nm on a multiwell plate reader.
4. If the plate cannot be read immediately, add 50 µL of 3 M HCl or 3 M H₂SO₄ solution per 200 µL of solution. Read stopped reactions at 492 nm.

Troubleshooting

If the background is too high:

1. Use a blocking step prior to the application of the primary antibody. Normal serum (5% v/v) from the same species as the host of the second antibody generally produces the best results.
2. Additional blocking agents for an ELISA are:
 - 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0 (Cat. No. T9039).
 - 1% BSA containing 0.05% TWEEN® 20 in 50 mM TBS, pH 8.0.
 - 3% nonfat-dried milk in 0.01 M TBS (Cat. No. P2194). Do not use milk as a blocking agent when using avidin-biotin systems.
3. Use 0.05% TWEEN® 20 in all washing and antibody diluent buffers.
4. Run control wells without the primary antibody to check for nonspecific reactivity of the secondary antibody.
5. Titer the primary antibody and the conjugate to optimize working dilutions.

If no color develops or the color is too faint:

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody.
3. Determine if the enzyme conjugate is active by mixing a small sample of substrate and conjugate together in a tube.
4. Increase the reaction time or temperature.
5. Adjust the concentration of the coating antigen.
6. Consider using an amplifying system such as avidin-biotin.

References

1. Wolters, G. *et al.*, *J. Clin. Path.*, **29(10)**, 873-879 (1976).
2. Bovaird, J.H. *et al.*, *Clin. Chem.*, **28(12)**, 2423-2426 (1982).
3. Porstmann, B. *et al.*, *J. Clin. Chem. Clin. Biochem.*, **19(7)**, 435-439 (1981).
4. Yang, Jin Ye, "Development of a receptor internalization assay for measuring and analysing RGS9-2 and palmitoyl-CoA transferase activity in HEK cells". University of Toronto, M.Sc. thesis, p. 21 (2015).

5. Maurer, Tobias, "CpG-DNA-antigen conjugates: a new class of therapeutics?". Technische Universität München, Dr. med. dissertation, p. 18 (2004).
6. Klima, Cassidy, "Using comparative genomics to identify virulence traits and vaccine candidates in *Mannheimia haemolytica*". University of Saskatchewan, Ph.D. dissertation, p. 118 (2015).
7. Oczypok, Elizabeth Ann, "Receptor for Advanced Glycation Endproducts Mediates Allergic Airway Inflammation via Group 2 Innate Lymphoid Cells". University of Pittsburgh School of Medicine, Ph.D. dissertation, pp. 62, 66 (2015).
8. Zhang, Boyang, "Functional and Structural Insights into the First and Second Intracellular Domains for D₁-Class Dopaminergic Receptors". University of Ottawa, Ph.D. dissertation, p. 58 (2015).
9. Xu, Ziyang, "Designing Synthetic DNA Encoded Immunotherapeutics And Nanoparticle Vaccines For Enhanced Immunity-Mediated Protection". University of Pennsylvania, Ph.D. dissertation, p. 27 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, SIGMAFAST and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.
© 2009-2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
P9187pis Rev 09/22 CS,GCY,MAM

**MILLIPORE
SIGMA**